bioSeedin

?? ?????????????? ???????????????? ???????????????? (??????????????) China's Next-Generation Oncology Innovators: A Deep Dive into BsAbs, ADCs, and Cell Therapies ?? Date: April 2nd, ?7-9 am BJT | April 1st, 7-9 PM EST ?? Format: Online As China's biopharma industry gains momentum globally, its advancements in bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and cell therapies are attracting international attention. Join us to explore cutting-edge pipelines, strategic visions, and partnership opportunities with five leading Chinese biotech companies. Agenda Highlights: ?? Company Presentations: Discover the latest in BsAbs, ADCs, and cell therapies. ?? Global Partnerships: Insights into cross-border licensing and co-development deals. ?? Oncology Trends: Learn about the evolving landscape of global oncology deals. Agenda (EST): 7:00-7:10: Open Remarks 7:10-7:30: HanX Bio 7:30-7:50: CorreGene 7:50-8:10: KangaBio 8:10-8:30: ICT Bio 8:30-8:50: TBD 8:50-9:00: Summary Keynote Speakers: ?? Judge: Adrian He Adrian He, Business Development Project Leader, ROCHE Roche ??? Host: Kenneth C. Chen, Ph.D., MBA, Kenneth Chih-Wei Chen BD Manager (US & EU), bioSeedin bioSeedin Featured Companies: HanX Biopharmaceuticals: Next-gen immunotherapy (PD-1 & CTLA4). Kanga Biotechnology: Immunoagonist predrug molecules. Innovative Cellular Therapeutics Innovative Cellular Therapeutics (ICT): CoupledCAR? platform for solid tumors. CorreGene Biotechnology CorreGene Biotechnology : Novel T-cell Engagers based on TCR. ?? Register now to secure your spot and connect with China's leading oncology innovators! ??https://lnkd.in/gAfsp26k #OncologyInnovation #Biopharma #ChinaBiotech #ADCs #BsAbs #CellTherapy #InnoXpo #bioSeedin #PharmaDeals #BiotechNews

???????????????? ?????? ???????????????? ????????: ???????????? ???????????? ?????????????????? ?????????? & ?????????????????????? ?? June 15th, 2025 | 1–7 PM (EST) ?? The Engine, 750 Main St, Cambridge, MA Hosted by bioSeedin bioSeedin, this exclusive event brings together global biopharma leaders to explore licensing trends and showcase innovation across oncology, autoimmune, metabolic, CNS, and more. ?? Panel: Global Licensing Trends ?? Roadshow Presentations: Novel MOAs, BIC potential, bsADC, RDC, small molecules (PCC–Phase 1/2) ?? Networking Dinner: Connect with top-tier innovators & BD leaders ?? Meet Our Esteemed Judges: Nicola La Monica, PhD Nicola La Monica – Johnson & Johnson Johnson & Johnson Alexandria (Alex) Cogdill, PhD Alexandria (Alex) Cogdill, MEng, PhD – Daiichi Sankyo Daiichi Sankyo Dan Zheng Dan Z. – Takeda Takeda ?? Biopharma BD/C-level execs and investors register FREE! ?? Register now via Free Pass: https://lnkd.in/guMEnd94 Don’t miss this one-of-a-kind opportunity to partner, learn, and lead. #InnoXpo2025 #bioSeedin #BIO2025 #PharmaBD #BiotechInnovation #Licensing #Partnering #NetworkingEvent

?????????? ???????? ???????????????????????? ?????????????????? ???????????????? ???? ???????? ?????????????? ?????? ?????? ???????????????? ???????????????? ???? ???????????????????? & ???????????????? Monte Rosa Therapeutics (Nasdaq: GLUE) Monte Rosa Therapeutics shared Q4 financials and major pipeline updates, highlighting progress across its molecular glue degrader (MGD) portfolio: ?? MRT-6160 (VAV1-directed MGD): ? Phase 1 data show >90% VAV1 degradation, strong T/B cell suppression, and cytokine inhibition (e.g., IL-2, IFN-γ, IL-17A). ? Favorable safety profile supports entry into Phase 2 trials for immune-mediated diseases. ? Ongoing collaboration with Novartis; $150M upfront + up to $2.1B in milestones. ?? MRT-2359 (GSPT1-directed MGD): ? Early clinical signals in castration-resistant prostate cancer (CRPC), including a confirmed partial response and PSA drop (-90%). ? Development will focus on CRPC, deprioritizing SCLC, NSCLC, and NE tumors. ? Further data expected in H2 2025. ?? MRT-8102 (NEK7-directed MGD): ? IND filing on track for H1 2025. Targets inflammatory conditions driven by IL-1β and NLRP3. ? Strong preclinical safety profile; human trials to follow. ?? Pipeline & Platform: ? Advancing CNS-penetrant NEK7 program (2026 IND). ? CDK2 & CCNE1-directed MGDs progressing toward 2026 INDs. ? QuEEN? engine continues to identify novel I&I drug candidates. ?? Cash runway into 2028, supporting multiple clinical proof-of-concept readouts. ?? CEO Markus Warmuth, M.D. Markus Warmuth: “These data reinforce the power of our MGD platform in tackling challenging diseases and enable us to advance multiple promising programs toward the clinic.” #MolecularGlueDegraders #Immunology #Oncology #CRPC #AutoimmuneDiseases #Novartis #VAV1 #NEK7 #CDK2 #CCNE1 #ClinicalTrials #PharmaPipeline #TargetedTherapies #PrecisionMedicine #GLU

???????????? ???? ?????????????? ???????? ??????’?? ???????????????????? ?????????????? ???????? ?????????????? ?????? ???????? ??-???????? ?????????????????? Sanofi Sanofi announced it will acquire DR-0201, Dren Bio’s Dren Bio, Inc. CD20-directed bispecific myeloid cell engager, in a deal worth $600M upfront. DR-0201 is designed to induce deep B-cell depletion by targeting tissue-resident and trafficking myeloid cells, showing strong potential in pre-clinical and early clinical studies for refractory B-cell mediated autoimmune diseases like lupus. By engaging myeloid cells for targeted phagocytosis, DR-0201 may offer a novel path to reset the adaptive immune system, aiming for sustained, treatment-free remission. ?? Houman Ashrafian Houman Ashrafian, Sanofi Head of R&D: “This acquisition strengthens our pipeline and brings us closer to becoming the leader in immunology.” ?? Nenad Tomasevic Nenad Tomasevic, CEO of Dren Bio: “Sanofi is the ideal partner to unlock the full potential of deep B-cell depletion for patients.” This move reflects Sanofi’s continued investment in breakthrough immunology therapies through strategic acquisitions and internal innovation. #Immunology #AutoimmuneDiseases #BCelldepletion #BispecificAntibodies #MyeloidCellEngager #ImmuneReset #MergersAndAcquisitions #Sanofi #DrenBio #PipelineExpansion

???????????? ?????????????????????????????? ?????? ?????????? ???????????????? ?????????????????? ?????????????????????????? ???? ?????????????? ????????????????-?????????? ???????????? ?????????????????? Oxford BioTherapeutics (OBT) Oxford BioTherapeutics has entered a multi-year collaboration with Roche Roche to discover and develop novel antibody-based therapeutics for cancer treatment. The collaboration leverages OBT’s OGAP?-Verify discovery platform and Roche’s drug development expertise to advance multiple oncology targets. OBT will receive up to $36 million in upfront payments and may earn over $1 billion in milestone payments, plus royalties on net sales. Roche will drive further research, development, and commercialization of validated targets. “We are proud to partner with Roche, a global leader in oncology, to accelerate the discovery of novel cancer targets,” said Dr. Christian Rohlff Christian Rohlff, CEO of OBT. “This collaboration enhances our ability to bring new treatments to patients.” “By combining Roche’s expertise with OBT’s innovative platform, we aim to unlock new possibilities in cancer treatment,” said Boris L. Za?tra Boris L. Za?tra, Head of Corporate Business Development at Roche. This partnership underscores a shared commitment to advancing first-in-class antibody-based therapeutics and addressing major unmet needs in oncology. #Oncology #CancerResearch #Biotech #ImmunoOncology #AntibodyTherapeutics #Pharma #DrugDiscovery #Innovation #Roche #OxfordBioTherapeutics

???????????? ?????? ???????????? ???? ?????????????????? ?????????????????? ???????? ??????????? ???? The biopharma industry is evolving rapidly, and the demand for microbial-derived biologics—from antibody fragments and nanobodies to enzymes and plasmid DNA—is surging. But how do we ensure high-yield, scalable, and cost-effective production to support next-generation therapies? Enter EffiX? – a cutting-edge microbial expression platform designed to accelerate biotherapeutic development with unparalleled efficiency. ?? High Yield & Scalability – Unlock the full potential of microbial systems ?? Consistent Quality & Stability – Engineered for reliable performance ?? Streamlined Processes – From early R&D to commercial manufacturing Join us for Webinar No. 209: EffiX? Global Launch and discover how this next-gen CMC solution can empower your biologics pipeline. ?? Date & Time: ?? March 26 | 11:00 AM - 12:00 PM (EDT) | 4:00 - 5:00 PM (BST) ?? Speaker: Dr. Zhaopeng Li Dr. Zhaopeng Li, Senior Director at WuXi Biologics WuXi Biologics ?? 20+ years of expertise in recombinant protein expression & upstream process development ?? Agenda Highlights: ? Industry trends driving microbial biologics innovation ? Deep dive into the EffiX? full-process solution ? Real-world case studies of successful applications ?? Don't miss out—register now and stay ahead in the future of biopharma! ?? Register Here :https://lnkd.in/gyEsBMcv #Biopharma #CMC #MicrobialBiologics #EffiX #AntibodyFragments #PlasmidDNA #Enzymes #WuXiBiologics #DrugDevelopment #BiotechInnovation

???????????????? ?????????????????? ???????????????? ?????????? ?????? ?????????????? ?????? ?????????????????????? ???????????????????????? ?????????????????????? ???? ?????? Novartis Novartis has reported strong Phase III results for investigational intrathecal onasemnogene abeparvovec (OAV101 IT) in patients with spinal muscular atrophy (SMA). In the STEER study, OAV101 IT showed a statistically significant 2.39-point improvement on the HFMSE vs. 0.51 points in the sham control group (P=0.0074). In the STRENGTH study, OAV101 IT stabilized motor function over 52 weeks in patients who had previously discontinued nusinersen or risdiplam. Safety findings were consistent, with the most common adverse events being respiratory infections and fever. These results, presented at the MDA Clinical and Scientific Conference, highlight OAV101 IT’s potential as a one-time gene therapy for a broad SMA population. Novartis plans to submit regulatory applications in H1 2025. #SMA #GeneTherapy #Novartis #RareDisease #Biotech #MedicalResearch #Innovation #OneTimeTreatment #Neuroscience #PhaseIII #OAV101

???????????????????????? ?????????????????? ???????????????? ?????????? ???? ?????????????? ?????? ??????-??????-???? ???? ?????? EnteroBiotix EnteroBiotix has reported promising topline data from its Phase 2a TrIuMPH study evaluating EBX-102-02, a full-spectrum microbiome-based drug, in patients with moderate to severe IBS with constipation (IBS-C). The treatment showed clinically meaningful improvements across key efficacy measures, including IBS symptom severity, stool consistency, and abdominal pain, with sustained benefits through follow-up. EBX-102-02 was also well-tolerated, with no serious adverse events. Microbiome analysis confirmed a significant shift in gut composition, supporting its potential as a first-in-class therapy for IBS. Final data, including results from IBS with diarrhea (IBS-D) patients, is expected in Q3 2025, with plans for a Phase 2b trial to further assess efficacy. #MicrobiomeTherapy #IBS #GutHealth #ClinicalTrials #Biotech #PharmaInnovation #EnteroBiotix

?????????????? ???????????????????????? ?????????????? ???????? ???? ?????? ?????? ????????????????? (????????????????????) ???? ???????? Travere Therapeutics Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for FILSPARI? (sparsentan) as a potential treatment for focal segmental glomerulosclerosis (FSGS). If approved, FILSPARI could become the first FDA-approved therapy for this rare kidney disease, a leading cause of kidney failure. The submission is based on Phase 3 DUPLEX and Phase 2 DUET studies, which demonstrated that FILSPARI provided significant and sustained reductions in proteinuria, compared to irbesartan, in both pediatric and adult FSGS patients. The FDA review decision is expected in Q2 2025. Additionally, the FDA has determined that Risk Evaluation and Mitigation Strategy (REMS) monitoring for embryo-fetal toxicity is no longer necessary. Travere plans to amend its REMS submission accordingly while awaiting a decision on liver monitoring modifications, with a PDUFA target date of August 28, 2025. #Biopharma #RareDisease #KidneyDisease #FSGS #Nephrology #DrugDevelopment #FDAApproval #ClinicalTrials #Pharmaceuticals #HealthcareInnovation #TravereTherapeutics #PrecisionMedicine #MedicalResearch

?? We’re Hiring – Business Development Director/Manager ?? bioSeedin bioSeedin, a global leader in drug asset management & licensing, is looking for a Business Development Director/Manager to drive partnerships across the US, Europe, and Asia. ?? What You’ll Do: ? Identify & evaluate licensing opportunities ? Lead deal negotiations & project management ? Build relationships with biotech, pharma & VC partners ? Represent bioSeedin at global conferences ?? What We’re Looking For: ?? Master’s, PhD, or MD in life sciences ?? 5+ years in biotech/pharma/VC (3+ in BD) ?? Proven deal-making & industry connections ?? Salary: $110,000 - $140,000 DOE + Bonus/Commission Join us in shaping the future of biotech! Apply now! #Hiring #BusinessDevelopment #Biotech #Pharma #BD